Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
NCT04056975
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
54
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed or Refractory B-cell Lymphoma
Interventions
BIOLOGICAL:
Recombinant Anti-CD19m-CD3 Antibody Injection
Sponsor
EVIVE Biotechnology
Collaborators
[object Object]